News/ News/ News/ Oncology/ R&D Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde Phil Taylor chemotherapy, Ipsen, Oncology, Onivyde, Servier, small cell lung cancer 0 Comment Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a Share X Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde https://pharmaphorum.com/news/phase-3-lung-cancer-fail-dents-prospects-of-ipsen-serviers-onivyde/